|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fodale V, Pierobon M, Liotta L and
Petricoin E: Mechanism of cell adaptation: When and how do cancer
cells develop chemoresistance? Cancer J. 17:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Croce JC and McClay DR: Evolution of the
Wnt pathways. Methods Mol Biol. 469:3–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu M, Ting DT, Stott SL, Wittner BS,
Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, et
al: RNA sequencing of pancreatic circulating tumour cells
implicates WNT signalling in metastasis. Nature. 487:510–513. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fu L, Zhang C, Zhang LY, Dong SS, Lu LH,
Chen J, Dai Y, Li Y, Kong KL, Kwong DL, et al: Wnt2 secreted by
tumour fibroblasts promotes tumour progression in oesophageal
cancer by activation of the Wnt/β-catenin signalling pathway. Gut.
60:1635–1643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pinto D, Gregorieff A, Begthel H and
Clevers H: Canonical Wnt signals are essential for homeostasis of
the intestinal epithelium. Genes Dev. 17:1709–1713. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sansom OJ, Reed KR, Hayes AJ, Ireland H,
Brinkmann H, Newton IP, Batlle E, Simon-Assmann P, Clevers H,
Nathke IS, et al: Loss of Apc in vivo immediately perturbs Wnt
signaling, differentiation, and migration. Genes Dev. 18:1385–1390.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB,
Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al: Oncogenic
pathway combinations predict clinical prognosis in gastric cancer.
PLoS Genet. 5:e10006762009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clements WM, Wang J, Sarnaik A, Kim OJ,
MacDonald J, Fenoglio-Preiser C, Groden J and Lowy AM: beta-catenin
mutation is a frequent cause of Wnt pathway activation in gastric
cancer. Cancer Res. 62:3503–3506. 2002.PubMed/NCBI
|
|
14
|
Ikenoue T, Ijichi H, Kato N, Kanai F,
Masaki T, Rengifo W, Okamoto M, Matsumura M, Kawabe T, Shiratori Y,
et al: Analysis of the beta-catenin/T cell factor signaling pathway
in 36 gastrointestinal and liver cancer cells. Jpn J Cancer Res.
93:1213–1220. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song X, Xin N, Wang W and Zhao C:
Wnt/β-catenin, an oncogenic pathway targeted by H. pylori in
gastric carcinogenesis. Oncotarget. 6:35579–35588. 2015.PubMed/NCBI
|
|
16
|
Kolligs FT, Bommer G and Göke B:
Wnt/beta-catenin/tcf signaling: A critical pathway in
gastrointestinal tumorigenesis. Digestion. 66:131–144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
18
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
López-Novoa JM and Nieto MA: Inflammation
and EMT: An alliance towards organ fibrosis and cancer progression.
EMBO Mol Med. 1:303–314. 2009. View Article : Google Scholar
|
|
20
|
Talbot LJ, Bhattacharya SD and Kuo PC:
Epithelial-mesenchymal transition, the tumor microenvironment, and
metastatic behavior of epithelial malignancies. Int J Biochem Mol
Biol. 3:117–136. 2012.PubMed/NCBI
|
|
21
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
24
|
Liu J, Ruan B, You N, Huang Q, Liu W, Dang
Z, Xu W, Zhou T, Ji R, Cao Y, et al: Downregulation of miR-200a
induces EMT phenotypes and CSC-like signatures through targeting
the β-catenin pathway in hepatic oval cells. PLoS One.
8:e794092013. View Article : Google Scholar
|
|
25
|
Chen Z, Saad R, Jia P, Peng D, Zhu S,
Washington MK, Zhao Z, Xu Z and El-Rifai W: Gastric adenocarcinoma
has a unique microRNA signature not present in esophageal
adenocarcinoma. Cancer. 119:1985–1993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang L, Guo F, Huo B, Lv Y, Wang Y and
Liu W: Expression and clinical significance of the microRNA-200
family in gastric cancer. Oncol Lett. 9:2317–2324. 2015.PubMed/NCBI
|
|
27
|
Barron N, Keenan J, Gammell P, Martinez
VG, Freeman A, Masters JR and Clynes M: Biochemical relapse
following radical prostatectomy and miR-200a levels in prostate
cancer. Prostate. 72:1193–1199. 2012. View Article : Google Scholar
|
|
28
|
Guttilla IK, Adams BD and White BA: ERα,
microRNAs, and the epithelial-mesenchymal transition in breast
cancer. Trends Endocrinol Metab. 23:73–82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons
DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, et
al: miR-200 Inhibits lung adenocarcinoma cell invasion and
metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011.
View Article : Google Scholar :
|
|
30
|
Shinozaki A, Sakatani T, Ushiku T, Hino R,
Isogai M, Ishikawa S, Uozaki H, Takada K and Fukayama M:
Downregulation of microRNA-200 in EBV-associated gastric carcinoma.
Cancer Res. 70:4719–4727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao Q, Mani RS, Ateeq B, Dhanasekaran SM,
Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, et al:
Coordinated regulation of polycomb group complexes through
microRNAs in cancer. Cancer Cell. 20:187–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X, et al: miR-141 and miR-200a act on ovarian
tumorigenesis by controlling oxidative stress response. Nat Med.
17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su J, Zhang A, Shi Z, Ma F, Pu P, Wang T,
Zhang J, Kang C and Zhang Q: MicroRNA-200a suppresses the
Wnt/β-catenin signaling pathway by interacting with β-catenin. Int
J Oncol. 40:1162–1170. 2012.PubMed/NCBI
|
|
34
|
Cong N, Du P, Zhang A, Shen F, Su J, Pu P,
Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a
promotes EMT and tumor growth through the wnt/β-catenin pathway by
targeting the E-cadherin repressors ZEB1/ZEB2 in gastric
adenocarcinoma. Oncol Rep. 29:1579–1587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang K, Zhang JX, Han L, You YP, Jiang T,
Pu PY and Kang CS: MicroRNA roles in beta-catenin pathway. Mol
Cancer. 9:2522010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He Y, Wang J, Liu X, Zhang L, Yi G, Li C,
He X, Wang P and Jiang H: Toosendanin inhibits hepatocellular
carcinoma cells by inducing mitochondria-dependent apoptosis.
Planta Med. 76:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang MZ, Wang ZF and Shi YL: Involvement
of cytochrome c release and caspase activation in
toosendanin-induced PC12 cell apoptosis. Toxicology. 201:31–38.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu JC, Min ZD and Ip NY: Melia toosendan
regulates PC12 Cell differentiation via the activation of protein
kinase A and extracellular signal-regulated kinases. Neurosignals.
13:248–257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang B, Wang ZF, Tang MZ and Shi YL:
Growth inhibition and apoptosis-induced effect on human cancer
cells of toosendanin, a triterpenoid derivative from Chinese
traditional medicine. Invest New Drugs. 23:547–553. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang G, Feng CC, Chu SJ, Zhang R, Lu YM,
Zhu JS and Zhang J: Toosendanin inhibits growth and induces
apoptosis in colorectal cancer cells through suppression of
AKT/GSK-3β/β-catenin pathway. Int J Oncol. 47:1767–1774. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Li B, Zhang Y, Xiang CP, Li YY and
Wu XL: Serial observations on an orthotopic gastric cancer model
constructed using improved implantation technique. World J
Gastroenterol. 17:1442–1447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Clardy J and Walsh C: Lessons from natural
molecules. Nature. 432:829–837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mishra BB and Tiwari VK: Natural products:
An evolving role in future drug discovery. Eur J Med Chem.
46:4769–4807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang ZY and Ge HY: Micrometastasis in
gastric cancer. Cancer Lett. 336:34–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Janda E, Lehmann K, Killisch I, Jechlinger
M, Herzig M, Downward J, Beug H and Grünert S: Ras and TGF[beta]
cooperatively regulate epithelial cell plasticity and metastasis:
Dissection of Ras signaling pathways. J Cell Biol. 156:299–313.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nawshad A, Lagamba D, Polad A and Hay ED:
Transforming growth factor-beta signaling during
epithelial-mesenchymal transformation: Implications for
embryogenesis and tumor metastasis. Cells Tissues Organs.
179:11–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shinto O, Yashiro M, Kawajiri H, Shimizu
K, Shimizu T, Miwa A and Hirakawa K: Inhibitory effect of a TGFbeta
receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous
gastric cancer cells. Br J Cancer. 102:844–851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu Y, Liu Y, Qian Y, Dai X, Yang L, Chen
J, Guo S and Hisamitsu T: Research on the efficacy of Celastrus
Orbiculatus in suppressing TGF-β1-induced epithelial-mesenchymal
transition by inhibiting HSP27 and TNF-α-induced NF-κB/Snail
signaling pathway in human gastric adenocarcinoma. BMC Complement
Altern Med. 14:4332014. View Article : Google Scholar
|
|
50
|
Ye Z, Li J, Han X, Hou H, Chen H, Zheng X,
Lu J, Wang L, Chen W, Li X, et al: TET3 inhibits TGF-β1-induced
epithelial-mesenchymal transition by demethylating miR-30d
precursor gene in ovarian cancer cells. J Exp Clin Cancer Res.
35:722016. View Article : Google Scholar
|
|
51
|
Ma M, He M, Jiang Q, Yan Y, Guan S, Zhang
J, Yu Z, Chen Q, Sun M, Yao W, et al: miR-487a promotes
TGF-β1-induced EMT, the migration and invasion of breast cancer
cells by directly targeting MAGI2. Int J Biol Sci. 12:397–408.
2016. View Article : Google Scholar :
|
|
52
|
Cai C and Zhu X: The Wnt/β-catenin pathway
regulates self-renewal of cancer stem-like cells in human gastric
cancer. Mol Med Rep. 5:1191–1196. 2012.PubMed/NCBI
|
|
53
|
Park EJ, Chung HJ, Park HJ, Kim GD, Ahn YH
and Lee SK: Suppression of Src/ERK and GSK-3/β-catenin signaling by
pinosylvin inhibits the growth of human colorectal cancer cells.
Food Chem Toxicol. 55:424–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan
J, Wu J and Li M: MicroRNA-374a activates Wnt/β-catenin signaling
to promote breast cancer metastasis. J Clin Invest. 123:566–579.
2013.PubMed/NCBI
|
|
55
|
Kikuchi A, Yamamoto H, Sato A and
Matsumoto S: New insights into the mechanism of Wnt signaling
pathway activation. Int Rev Cell Mol Biol. 291:21–71. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Seo JH, Jeong ES and Choi YK: Therapeutic
effects of lentivirus-mediated shRNA targeting of cyclin D1 in
human gastric cancer. BMC Cancer. 14:1752014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Burlacu A: Regulation of apoptosis by
Bcl-2 family proteins. J Cell Mol Med. 7:249–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi
K, Gu Y and Fang G: Long non-coding RNA GHET1 promotes gastric
carcinoma cell proliferation by increasing c-Myc mRNA stability.
FEBS J. 281:802–813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang BG, Du T, Zang MD, Chang Q, Fan ZY,
Li JF, Yu BQ, Su LP, Li C, Yan C, et al: Androgen receptor promotes
gastric cancer cell migration and invasion via AKT-phosphorylation
dependent upregulation of matrix metalloproteinase 9. Oncotarget.
5:10584–10595. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Saydam O, Shen Y, Würdinger T, Senol O,
Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens
RM, et al: Downregulated microRNA-200a in meningiomas promotes
tumor growth by reducing E-cadherin and activating the
Wnt/beta-catenin signaling pathway. Mol Cell Biol. 29:5923–5940.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Giraldez AJ, Mishima Y, Rihel J, Grocock
RJ, Van Dongen S, Inoue K, Enright AJ and Schier AF: Zebrafish
MiR-430 promotes deadenylation and clearance of maternal mRNAs.
Science. 312:75–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
